Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
.jpg)
Sichenzia Ross Ference LLP
Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.
Visit SRF's LinkedIn page
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019
